SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst. 2008;100:1282-1289.
  • 2
    Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331:1199-1203.
  • 3
    Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514-523.
  • 4
    Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501-513.
  • 5
    Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072.
  • 6
    Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17:600-606.
  • 7
    Rinke A, Muller HH, Schade-Brittinger C, et al; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656-4663.
  • 8
    Clark OH, Benson AB 3rd, Berlin JD, et al; NCCN Neuroendocrine Tumors Panel Members. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Netw. 2009;7:712-747.
  • 9
    Oberg K, Akerstrom G, Rindi G, Jelic S, ESMO Guidelines Working Group. Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl 5):v223-v227.
  • 10
    Eriksson B, Kloppel G, Krenning E, et al; Frascati Consensus Conference participants. Consensus guidelines for the management of patients with digestive neuroendocrine tumors–well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology. 2008;87:8-19.
  • 11
    Boudreaux JP, Klimstra DS, Hassan MM, et al; North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas. 2010;39:753-766.
  • 12
    National Cancer Institute. Surveillance, Epidemiology and End Results Program. seer.cancer.gov/. Accessed March 3, 2014.
  • 13
    Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(suppl 8):IV-3-IV-18.
  • 14
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
  • 15
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
  • 16
    Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46:1075-1079; discussion 1081-1090.
  • 17
    Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258-1267.
  • 18
    Bird CE, Shugarman LR, Lynn J. Age and gender differences in health care utilization and spending for Medicare beneficiaries in their last years of life. J Palliat Med. 2002;5:705-712.
  • 19
    Chou AF, Scholle SH, Weisman CS, Bierman AS, Correa-de-Araujo R, Mosca L. Gender disparities in the quality of cardiovascular disease care in private managed care plans. Womens Health Issues. 2007;17:120-130.
  • 20
    Garg PP, Furth SL, Fivush BA, Powe NR. Impact of gender on access to the renal transplant waiting list for pediatric and adult patients. J Am Soc Nephrol. 2000;11:958-964.
  • 21
    Earle CC, Neumann PJ, Gelber RD, Weinstein MC, Weeks JC. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol. 2002;20:1786-1792.
  • 22
    IPSEN Innovation for Patient Care. Detailed Results of the Phase III CLARINET Study at the European Cancer Congress 2013 on 28 September 2013. ipsen.com/wp-content/uploads/2013/09/PR-Dates-Late-breaking-news-and-Press-conference-Clarinet-EN.pdf. Accessed March 3, 2014.
  • 23
    Surveillance, Epidemiology, and End Results (SEER) Program. Research Data (1973-2010). Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences Surveillance Research Program, Surveillance Systems Branch; 2013, based on the November 2012 submission.